Page 119 - CIBER-BBN2016-ENG

Most relevant scientific articles
• Grimaldi N., Andrade F., Segovia N., Ferrer-Tasies L., Sala S., Veciana J. et al. Lipid-based nanovesicles for nanomedicine. Chemical Society Reviews. 2016;45(23):6520-6545.
• Yuan L., Franco C., Crivillers N., Mas-Torrent M., Cao L., Sangeeth C.S.S. et al. Chemical control over the energy-level alignment in a two-terminal junction. Nature Communications. 2016;7.
• Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
• Souto M., Lloveras V., Vela S., Fumanal M., Ratera I., Veciana J. Three Redox States of a Diradical Acceptor-Donor-Acceptor Triad: Gating the Magnetic Coupling and the Electron Delocalization. Journal of Physical Chemistry Letters. 2016;7(12):2234-2239.
• Leonardi F., Casalini S., Zhang Q., Galindo S., Gutiérrez D., Mas-Torrent M. Electrolyte-Gated Organic Field-Effect Transistor Based on a Solution Sheared Organic Semiconductor Blend. Advanced Materials. 2016;28(46):10311-10316.
Highlights
• 28 scientific publications in JCR indexed journals with an average impact factor of 8,010.
• Application of 2 international patents (US and Europe).
• 16 invited lectures given in international conferences.
• Participation on the activities of EU FP7 and H2020 projects: NANO2FUN, COMMON SENSE, ACMOL,
SAM-Tune GAIN, OSES-Int-Log, and i-SWITCH
• Participation in three RETOS COLABORACIÓN projects: TERARMET consortium to carry out the
project “Desarrollo de terapias para el tratamiento de enfermedades raras metabólicas congénitas”, coordinated by the company PRAXIS PHARMACEUTICALS, UNDERLIPIDS consortium to carry
out “Nanoparticulas sólidas lipídicas para administración subcutánea de compuestos marinos antitumorales”, coordinated by PHARMAMAR, and NANO4DERM consortium to carry out “Nanocápsulas conteniendo activos para el tratamiento tópico de enfermedades dermatológicas”, coordinated by ALMIRALL.
• Approval of H2020 project SMART4FABRY – “Smart multifunctional GLA-nanoformulation for Fabry disease”, under the coordination of CIBER by NANOMOL group and with a total budget of 5.844.509€
• Implementation of scientific activities of ERC Starting Grant project “e-GAMES”.
• Execution of scientific activities of CIBER-BBN intramural projects: NANOLYSO, NANOMETS, BIOFILM-
ATTACK, VASCUMAT, ORDECA
• Approval of two TECNIOspring fellowships funded by ACC1Ó-Generalitat where two experienced
researchers join the group to carry out 2-year projects on biomedicine.
• Coordination of the CIBER-BBN Transfer Project: “Functionalized nanoliposomes for the development
of therapies for intracellular-based diseases. Application to Fabry disease and homozygous familial
hypercholesterolemia (LIPOCELL)” in collaboration with the company BIOPRAXIS RESEARCH AIE.
• Approval of RIS3CAT NANONAFRES project ““Estudis preclinicis i clínics adreçats a l’aplicació de nano
vesícules (quatsomes) amb EGF úlceres venoses cròniques” to be executed together with several
clinical institutions in Catalonia.
• Implementation of scientific activities of EXPLORA projectS “Engineering Cell Vessels on Surfaces using
Dynamic Molecular Bio-Interfaces” and “Biosensors platform based on field effect organic transistors for
diagnosis of Alzheimer”.
• Implementation of scientific activities of BE-WELL project under MINECO RETOS DE LA SOCIEDAD
program. Approval of FANCY and MOTHER projects under same program 2016 call.
• Implementation of activities as Scientific Direction of the Large Scientifical and Technical Facility
NANBIOSIS.
BBN
Research Groups 119